Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZILSARTAN MEDOXOMIL vs DIASTAT ACUDIAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
Treatment of hypertension (FDA-approved),Off-label: heart failure, diabetic nephropathy
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
40 mg orally once daily. May increase to 80 mg once daily if needed.
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan.
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
High (>99%) to serum albumin.
97-99% bound primarily to albumin.
Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution.
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans.
Rectal gel: 80-100% relative to intravenous administration.
No dose adjustment required for GFR ≥15 m L/min/1.73 m². Not recommended for GFR <15 m L/min/1.73 m² due to lack of data.
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Not approved for use in pediatric patients (safety and efficacy not established).
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity.
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
none
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Fetal toxicity: avoid use in pregnancy,Hypotension in volume-depleted patients,Renal impairment: monitor renal function,Hyperkalemia: monitor potassium levels
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Pregnancy (second and third trimesters),Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min)
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness.
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown.
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
No dose adjustments during pregnancy; however, use is contraindicated in second and third trimesters due to fetal toxicity. If exposure occurs, discontinue as soon as possible.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
Take once daily at the same time each day with or without food.,Avoid becoming dehydrated; drink adequate fluids unless directed otherwise.,Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs.,Do not take with aliskiren if you have diabetes or renal impairment.,Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness.,May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you.,Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor.,Do not stop taking the medication without talking to your doctor.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
"The combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to a significant reduction in the antihypertensive and cardioprotective effects of azilsartan. NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis, which diminishes the vasodilatory and natriuretic actions that support blood pressure control mediated by ARBs. This interaction may result in loss of blood pressure control, increased risk of renal impairment (especially in volume-depleted or elderly patients), and potential antagonism of the renal protective effects of ARBs in conditions like heart failure or chronic kidney disease."
"Oxprenolol, a non-selective beta-blocker, may attenuate the compensatory sympathetic response to Azilsartan medoxomil-induced hypotension, potentially leading to an excessive drop in blood pressure. This combination can also result in reduced cardiac output due to additive negative chronotropic effects, increasing the risk of bradycardia and heart block. Clinically, patients may experience severe hypotension, dizziness, syncope, or exacerbated heart failure symptoms."
"The combination of timolol, a non-selective beta-blocker, with azilsartan medoxomil, an angiotensin II receptor blocker (ARB), may lead to an increased risk of hypotension, bradycardia, and additive antihypertensive effects. Timolol can antagonize the compensatory sympathetic response to azilsartan-induced vasodilation, potentially resulting in excessive blood pressure reduction. Additionally, both drugs can affect renal perfusion, raising the risk of renal impairment in susceptible patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZILSARTAN MEDOXOMIL vs DIASTAT ACUDIAL, answered by our medical review team.
AZILSARTAN MEDOXOMIL is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.. DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZILSARTAN MEDOXOMIL and DIASTAT ACUDIAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZILSARTAN MEDOXOMIL is: 40 mg orally once daily. May increase to 80 mg once daily if needed.. The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZILSARTAN MEDOXOMIL and DIASTAT ACUDIAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZILSARTAN MEDOXOMIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligo. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.